Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Bronchial Carcinoma Treated by Adjuvant Cancer Chemotherapy

Bronchial Carcinoma Treated by Adjuvant Cancer Chemotherapy Abstract Four prospective randomized trials were undertaken to evaluate single-drug chemotherapy after resection of bronchial carcinoma in men. The drugs studied were mechlorethamine hydrochloride, cyclophosphamide, and methotrexate. A total of 2,348 curative resections were carried out; 1,172 patients received adjuvant therapy after the resection and 1,176 underwent operation alone. The accumulated five- and ten-year survival rates were 24.8% and 13.5%, respectively, for the treatment group and 26.2% and 16.3% for the control group. The differences were not significant. It is therefore apparent that single-drug adjuvant therapy is not beneficial in the management of patients who have undergone a curative resection of a bronchial carcinoma. Involvement of lymph nodes in the specimen was associated with a significantly poorer prognosis, but cell type, other than oat cell, appeared not to affect the prognosis when a curative resection had been carried out. References 1. Shields TW, et al: Preoperative x-ray therapy as an adjuvant in the treatment of bronchogenic carcinoma . J Thorac Cardiovasc Surg 59:49-61, 1970. 2. Shields TW: Preoperative radiation therapy in the treatment of bronchial carcinoma . Cancer 30:1388-1394, 1972.Crossref 3. Higgins GA: Use of chemotherapy as an adjuvant to surgery for bronchogenic carcinoma . Cancer 30:1383-1387, 1972.Crossref 4. Brunner KW, Marthaler TH, Muller W: Unfavorable effects of long-term adjuvant chemotherapy with Endoxan in radically operated bronchogenic carcinoma . Eur J Cancer 7:285-294, 1971.Crossref 5. Selawry OS: Monochemotherapy of bronchogenic carcinoma with special reference to cell type . Cancer Chemother Rep 4:177-188, 1973. 6. Shields TW, Robinette CD: Long-term survivors after resection of bronchial carcinoma . Surg Gynecol Obstet 136:759-762, 1973. 7. Matthews MJ, et al: Frequency of residual and metastatic tumor in patients undergoing curative surgical resection for lung cancer . Cancer Chemother Rep 4:63-67, 1973. 8. Clinical Staging for Carcinoma of the Lung . Chicago, American Joint Committee for Cancer Staging and End Results Reporting, 1973. 9. Matthews MJ: Morphologic classification of bronchogenic carcinoma . Cancer Chemother Rep 4:299-301, 1973. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Surgery American Medical Association

Bronchial Carcinoma Treated by Adjuvant Cancer Chemotherapy

Loading next page...
 
/lp/american-medical-association/bronchial-carcinoma-treated-by-adjuvant-cancer-chemotherapy-8wC5EoNv1P
Publisher
American Medical Association
Copyright
Copyright © 1974 American Medical Association. All Rights Reserved.
ISSN
0004-0010
eISSN
1538-3644
DOI
10.1001/archsurg.1974.01360020189037
Publisher site
See Article on Publisher Site

Abstract

Abstract Four prospective randomized trials were undertaken to evaluate single-drug chemotherapy after resection of bronchial carcinoma in men. The drugs studied were mechlorethamine hydrochloride, cyclophosphamide, and methotrexate. A total of 2,348 curative resections were carried out; 1,172 patients received adjuvant therapy after the resection and 1,176 underwent operation alone. The accumulated five- and ten-year survival rates were 24.8% and 13.5%, respectively, for the treatment group and 26.2% and 16.3% for the control group. The differences were not significant. It is therefore apparent that single-drug adjuvant therapy is not beneficial in the management of patients who have undergone a curative resection of a bronchial carcinoma. Involvement of lymph nodes in the specimen was associated with a significantly poorer prognosis, but cell type, other than oat cell, appeared not to affect the prognosis when a curative resection had been carried out. References 1. Shields TW, et al: Preoperative x-ray therapy as an adjuvant in the treatment of bronchogenic carcinoma . J Thorac Cardiovasc Surg 59:49-61, 1970. 2. Shields TW: Preoperative radiation therapy in the treatment of bronchial carcinoma . Cancer 30:1388-1394, 1972.Crossref 3. Higgins GA: Use of chemotherapy as an adjuvant to surgery for bronchogenic carcinoma . Cancer 30:1383-1387, 1972.Crossref 4. Brunner KW, Marthaler TH, Muller W: Unfavorable effects of long-term adjuvant chemotherapy with Endoxan in radically operated bronchogenic carcinoma . Eur J Cancer 7:285-294, 1971.Crossref 5. Selawry OS: Monochemotherapy of bronchogenic carcinoma with special reference to cell type . Cancer Chemother Rep 4:177-188, 1973. 6. Shields TW, Robinette CD: Long-term survivors after resection of bronchial carcinoma . Surg Gynecol Obstet 136:759-762, 1973. 7. Matthews MJ, et al: Frequency of residual and metastatic tumor in patients undergoing curative surgical resection for lung cancer . Cancer Chemother Rep 4:63-67, 1973. 8. Clinical Staging for Carcinoma of the Lung . Chicago, American Joint Committee for Cancer Staging and End Results Reporting, 1973. 9. Matthews MJ: Morphologic classification of bronchogenic carcinoma . Cancer Chemother Rep 4:299-301, 1973.

Journal

Archives of SurgeryAmerican Medical Association

Published: Aug 1, 1974

References